Patient characteristics of the University of Michigan validation set
| Total, N = 871 . | GI GVHD*†, N = 167 . | No GVHD, N = 362 . | Non-GVHD enteritis‡, N = 52 . | Skin GVHD, N = 290 . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 50 (0-67) | 46 (0-68) | 48 (3-66) | 49 (0-70) | .003 |
| Disease, % | .002 | ||||
| Malignant | 99 (n = 165) | 92 (n = 334) | 96 (n = 50) | 97 (n = 282) | |
| Other | 1 (n = 2) | 8 (n = 28) | 4 (n = 2) | 3 (n = 8) | |
| Disease status at transplantation, %§ | .63 | ||||
| Other/low/intermediate risk | 64 (n = 105) | 69 (n = 232) | 68 (n = 34) | 68 (n = 192) | |
| High risk | 36 (n = 60) | 31 (n = 102) | 32 (n = 16) | 32 (n = 90) | |
| Donor type, % | < .001 | ||||
| Related donor | 45 (n = 75) | 64 (n = 233) | 54 (n = 28) | 40 (n = 115) | |
| Unrelated donor | 55 (n = 92) | 36 (n = 129) | 46 (n = 24) | 60 (n = 175) | |
| Donor match, % | < .001 | ||||
| Matched donor | 70 (n = 117) | 90 (n = 325) | 92 (n = 48) | 73 (n = 212) | |
| Mismatched donor | 30 (n = 50) | 10 (n = 37) | 8 (n = 4) | 27 (n = 78) | |
| Conditioning regimen intensity, % | .06 | ||||
| High intensity | 57 (n = 95) | 67 (n = 243) | 63 (n = 33) | 57 (n = 165) | |
| Moderate intensity | 43 (n = 72) | 33 (n = 119) | 37 (n = 19) | 43 (n = 125) | |
| Grade of GVHD at onset, % | |||||
| 0 | 0 (n = 0) | 100 (n = 362) | 100 (n = 52) | 0 (n = 0) | |
| I | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 69 (n = 201) | |
| Skin stage 1 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 41 (n = 118) | |
| Skin stage 2 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 29 (n = 83) | |
| II | 57 (n = 96) | 0 (n = 0) | 0 (n = 0) | 30 (n = 88) | |
| Isolated skin stage 3 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 30 (n = 88) | |
| Isolated upper GI stage 1† | 17 (n = 29) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| Lower GI stage 1† | 40 (n = 67) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| III-IV | 43 (n = 71) | 0 (n = 0) | 0 (n = 0) | 1 (n = 1) | |
| Isolated skin stage 4 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 1 (n = 1) | |
| GI stage 2† | 13 (n = 22) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| GI stage 3† | 16 (n = 27) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| GI stage 4† | 13 (n = 22) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| Median d after HCT (range) | 33 (11-216) | 31 (7-185) | 24 (7-93) | 28 (5-175) | < .001 |
| Total, N = 871 . | GI GVHD*†, N = 167 . | No GVHD, N = 362 . | Non-GVHD enteritis‡, N = 52 . | Skin GVHD, N = 290 . | P . |
|---|---|---|---|---|---|
| Median age, y (range) | 50 (0-67) | 46 (0-68) | 48 (3-66) | 49 (0-70) | .003 |
| Disease, % | .002 | ||||
| Malignant | 99 (n = 165) | 92 (n = 334) | 96 (n = 50) | 97 (n = 282) | |
| Other | 1 (n = 2) | 8 (n = 28) | 4 (n = 2) | 3 (n = 8) | |
| Disease status at transplantation, %§ | .63 | ||||
| Other/low/intermediate risk | 64 (n = 105) | 69 (n = 232) | 68 (n = 34) | 68 (n = 192) | |
| High risk | 36 (n = 60) | 31 (n = 102) | 32 (n = 16) | 32 (n = 90) | |
| Donor type, % | < .001 | ||||
| Related donor | 45 (n = 75) | 64 (n = 233) | 54 (n = 28) | 40 (n = 115) | |
| Unrelated donor | 55 (n = 92) | 36 (n = 129) | 46 (n = 24) | 60 (n = 175) | |
| Donor match, % | < .001 | ||||
| Matched donor | 70 (n = 117) | 90 (n = 325) | 92 (n = 48) | 73 (n = 212) | |
| Mismatched donor | 30 (n = 50) | 10 (n = 37) | 8 (n = 4) | 27 (n = 78) | |
| Conditioning regimen intensity, % | .06 | ||||
| High intensity | 57 (n = 95) | 67 (n = 243) | 63 (n = 33) | 57 (n = 165) | |
| Moderate intensity | 43 (n = 72) | 33 (n = 119) | 37 (n = 19) | 43 (n = 125) | |
| Grade of GVHD at onset, % | |||||
| 0 | 0 (n = 0) | 100 (n = 362) | 100 (n = 52) | 0 (n = 0) | |
| I | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 69 (n = 201) | |
| Skin stage 1 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 41 (n = 118) | |
| Skin stage 2 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 29 (n = 83) | |
| II | 57 (n = 96) | 0 (n = 0) | 0 (n = 0) | 30 (n = 88) | |
| Isolated skin stage 3 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 30 (n = 88) | |
| Isolated upper GI stage 1† | 17 (n = 29) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| Lower GI stage 1† | 40 (n = 67) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| III-IV | 43 (n = 71) | 0 (n = 0) | 0 (n = 0) | 1 (n = 1) | |
| Isolated skin stage 4 | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | 1 (n = 1) | |
| GI stage 2† | 13 (n = 22) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| GI stage 3† | 16 (n = 27) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| GI stage 4† | 13 (n = 22) | 0 (n = 0) | 0 (n = 0) | 0 (n = 0) | |
| Median d after HCT (range) | 33 (11-216) | 31 (7-185) | 24 (7-93) | 28 (5-175) | < .001 |
GI indicates gastrointestinal; HCT, hematopoietic cell transplantation; and CIBMTR, Center for International Blood and Marrow Transplant Research.
Including 29 patients with isolated upper GI GVHD and 138 with lower ± upper GI GVHD.
With or without other GVHD target organ involvement.
Including 13 patients with isolated upper GI non-GVHD enteritis and 39 patients with lower ± upper GI non-GVHD enteritis.
High risk of disease status at HCT is according to CIBMTR guidelines.